Efficacy and safety of the long-acting β₂-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

Abstract

Background

Olodaterol is a novel long-acting β₂-agonist with proven ≥24-hour duration of action in preclinical and clinical studies.

Objective

This randomized, double-blind, placebo-controlled, parallel-group study evaluated the dose response of once-daily (QD) olodaterol based on bronchodilator efficacy, safety, and pharmacokinetics over 4 weeks in Japanese patients with chronic obstructive pulmonary disease (COPD).

Methods

All eligible patients were randomized to receive 2 µg, 5 µg, or 10 µg of olodaterol or placebo for 4 weeks via the Respimat^® Soft Mist™ inhaler. The primary end point was the change from baseline in trough forced expiratory volume in 1 second (FEV₁) after 4 weeks of olodaterol treatment. Secondary end points included trough FEV₁ after 1 week and 2 weeks of treatment, FEV₁ area under the curve from 0 hour to 3 hours (AUC_0–3), peak FEV₁ from 0 hour to 3 hours (peak FEV₁), and corresponding forced vital capacity (FVC) responses. Rescue medication use, COPD symptoms, physician global evaluation, pharmacokinetics, and safety were also assessed.

Results

A total of 328 patients with COPD were randomized to receive treatment. All olodaterol doses assessed in the study showed statistically significant increases in trough FEV₁ compared to placebo at Day 29 (P<0.0001). Mean increases in peak FEV₁ and FEV₁ AUC_0–3 compared to placebo were also significant (P<0.0001). A clear dose–response relationship was observed across all treatment groups. FVC responses (trough and FVC AUC_0–3) supported FEV₁ outcomes. All doses of olodaterol were well tolerated, and no safety concerns were identified.

Conclusion

QD olodaterol demonstrated 24-hour bronchodilator efficacy and was well tolerated in Japanese patients with COPD.

Trial registration

ClinicalTrials.gov: NCT0824382.

Keywords:

• trough FEV₁
• trough FVC
• plasma concentration
• pulmonary function
• once-daily
• dose-finding

Introduction

Chronic obstructive pulmonary disease (COPD), characterized by airflow limitation that is not fully reversible and progressive deterioration in lung function,^1,2 is associated with chronic and progressive dyspnea, cough, and sputum production.³ The introduction of the long-acting β₂-agonists salmeterol and formoterol allowed effective maintenance treatment of COPD in patients with symptoms inadequately controlled by short-acting agents.^4,5 However, the 12-hour duration of action of these therapies necessitates twice-daily dosing.³ With the development of newer long-acting β₂-agonists, such as indacaterol, with a 24-hour duration of action,⁶ there is an intriguing possibility of a once-daily (QD) posology, particularly in combination with other QD long-acting muscarinic antagonists such as tiotropium, which may improve treatment adherence.⁷

Olodaterol has high selectivity for the human β₂-adrenoceptor, a potent, near full agonist response in vitro, and proven effective bronchoprotection over 24 hours in anesthetized guinea pigs and dogs in vivo.^8,9

This is the first study evaluating the effect of olodaterol in Japanese patients with COPD, and given its similarity to a recent study conducted in a Caucasian population (Study 1222.5), the study presented here will help to evaluate the ethnic sensitivity of the efficacy and safety of this therapy.¹⁰

This study was designed to confirm the 24-hour bronchodilator efficacy, pharmacokinetics, and safety of olodaterol QD administered via the Respimat^® Soft Mist™ inhaler (Boehringer Ingelheim, Ingelheim, Germany) in Japanese patients with COPD over 4 weeks of treatment and to determine the most appropriate dose for evaluation in Phase III study.

Methods

Study design

This was a 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study registered with ClinicalTrials.gov (NCT0824382). Following an initial screening, patients entered a 2- to 4-week screening period to determine clinical stability. All eligible patients were randomized to receive 2 µg, 5 µg, or 10 µg of olodaterol or placebo QD (all administered as two actuations) for 4 weeks via the Respimat^® Soft Mist™ inhaler (Figure 1). All patients were evaluated for a further 2 weeks following completion of the 4-week treatment period or discontinuation. Patients were permitted to use inhaled corticosteroids and short-acting anticholinergics throughout the study, as needed, and the short-acting β-adrenergic salbutamol (100 µg) was allowed as rescue medication, if required.

Figure 1 Study design: 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

Abbreviation: QD, once daily.

The study was approved by local ethics committees and was carried out according to the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, and local regulations. Prior to study initiation, the protocol was approved by the local institutional review boards at each institution, Independent Ethics Committee, and the Competent Authority. All patients provided written, informed consent prior to the study commencing.

Patients

Patients were enrolled into the study if they met the following inclusion criteria: age ≥40 years, current or ex-smokers with a smoking history of >10 pack-years, diagnosis of COPD, post-bronchodilator forced expiratory volume in 1 second (FEV₁) of ≥30% predicted normal and <80% predicted normal, and a post-bronchodilator FEV₁/forced vital capacity (FVC) <70%. Key exclusion criteria were as follows: a significant disease other than COPD (defined by the investigator as a disease that may put the patient at risk by participating in the study, influence study outcomes, or cause concern with regard to the patient’s ability to participate in the study), history of asthma or a total blood eosinophil count of ≥600/mm³, history of myocardial infarction within the past year, unstable or life-threatening cardiac arrhythmia or hospitalization for heart failure within the past year, marked prolongation of QT/QTc interval (QTc interval >450 ms), and experience of any respiratory infection or COPD exacerbation 6 weeks prior to the baseline assessment.

Study outcomes

The primary end point was change from baseline in trough FEV₁ after 4 weeks of treatment with olodaterol. Trough FEV₁ was defined as the mean of two FEV₁ values (60 minutes and 10 minutes prior to study medication inhalation) at the end of the dosing interval 24 hours after administration of olodaterol. Trough FEV₁ response was defined as the change from baseline in trough FEV₁. Baseline FEV₁ was the mean of two pre-treatment FEV₁ values (60 minutes and 10 minutes prior to first study medication inhalation). Secondary efficacy variables included trough FEV₁ after 1 week and 2 weeks of treatment, FEV₁ area under the curve from 0 hour to 3 hours (AUC_0–3) responses, peak FEV₁ from 0 hour to 3 hours (peak FEV₁), FVC, FVC AUC_0–3, and peak FVC from 0 hour to 3 hours (peak FVC) responses. Other observations included individual FEV₁ and FVC responses at each time point, weekly mean peak expiratory flow rate in the morning (predose) and evening, weekly rescue medication use, COPD symptom scores, and physician global evaluation (PGE).

Safety end points, including adverse events (AEs) and vital signs, were assessed in all treated patients receiving at least one dose of the study medication. Other safety assessments included routine blood chemistry (including potassium), hematology, and urinalysis. Potassium was carefully assessed.

Pharmacokinetic parameters evaluated after the first and last dose of study medication included the maximum measured concentration of the analyte in plasma (C_max), time from dosing to the maximum measured concentration of the analyte in plasma (t_max), and area under the concentration–time curve.

Assessments

Efficacy

The primary criterion for evaluation in this study was FEV₁. All qualifying pulmonary function tests (FEV₁ and FVC) and reversibility testing using salbutamol were conducted at the screening visit. FEV₁ and FVC pulmonary function tests were performed at Day 1, Week 1, Week 2, and Week 4 at 60 minutes and 10 minutes prior to study medication inhalation and at 30 minutes, 60 minutes, 120 minutes, and 180 minutes post-study medication inhalation. All pulmonary function testing was performed according to American Thoracic Society and European Respiratory Society criteria.¹¹

Rescue medication use was recorded in a patient diary, in which the patient recorded salbutamol use each day and night throughout the study, including screening and treatment periods.

The severity of COPD symptoms, including wheezing, shortness of breath, coughing, and tightness of chest, was recorded at baseline, at Weeks 1, 2, and 4 of the treatment period, and at follow-up, using the following assessment scale: 0= none, 1= mild, 2= moderate, and 3= severe.

PGE was carried out at baseline, at Weeks 1, 2, and 4 of the treatment period, and at follow-up. The assessments reflected the physicians’ opinion of the patients’ overall clinical condition based on the need for concomitant medication, number and severity of exacerbations, severity of cough, ability to exercise, and other relevant clinical observations. All evaluations were recorded by indication of the appropriate score from 1 (“poor”) to 8 (“excellent”), as done in previous studies.¹²

Safety assessments

Safety measurements included laboratory tests, vital signs (blood pressure and pulse rate), and 12-lead electrocardiogram. All AEs, irrespective of causality (as judged by physicians), were monitored throughout the study by checking patients’ paper diaries and asking patients for any changes in their health.

Pharmacokinetic assessments

Pharmacokinetics of olodaterol were evaluated in the target patient population by determining drug plasma concentrations following the first and last administrations of olodaterol. Plasma concentrations of olodaterol were determined by validated high-performance liquid chromatography coupled to tandem mass spectrometry assay.

Statistical analysis

The planned sample size of 80 evaluable patients per group was needed to demonstrate efficacy of both 5 µg and 10 µg of olodaterol against placebo with 86% power at a one-sided 2.5% level of significance. The full analysis set (for efficacy and pharmacokinetic analyses) consisted of all randomized patients with baseline data and at least one adequate measurement for one or more end points after ≥5 days of study medication inhalation. The per-protocol set comprised patients in the full analysis set with no important protocol violations. All treated patients who received at least one dose of study medication were included in the safety evaluation.

The primary analysis of trough FEV₁ was conducted using the analysis of covariance (ANCOVA) model, in which trough FEV₁ was compared between each of the olodaterol doses and placebo in a closed testing procedure. Sensitivity analyses were performed to confirm robustness of primary efficacy data and to assess the contribution of various baseline characteristics to the primary analysis model.

All secondary end points were also summarized using the ANCOVA model with terms for baseline, center, and treatment. The baseline was used as a linear covariate, and a separate ANCOVA was performed for each time point. All safety end points are summarized descriptively.

Results

Patient population

Written informed consent was obtained from a total of 515 Japanese patients, of whom 328 were randomized to receive study medication (Figure 2). In total, 15 patients prematurely discontinued from the study, primarily due to AEs (10 patients). Baseline patient characteristics were comparable across treatment groups (Table 1).

Table 1 Patient demographics and baseline characteristics

	Placebo (n=79)	Olodaterol
		2 µg QD (n=84)	5 µg QD (n=79)	10 µg QD (n=86)	Total (n=328)
Sex, n (%)
Male	75 (94.9)	79 (94.0)	76 (96.2)	80 (93.0)	310 (94.5)
Female	4 (5.1)	5 (6.0)	3 (3.8)	6 (7.0)	18 (5.5)
Mean (SD) age, years	68.9 (6.5)	68.9 (7.6)	70.1 (6.7)	69.3 (7.4)	69.3 (7.1)
Smoking status, n (%)
Current smokers	20 (25.3)	22 (26.2)	23 (29.1)	21 (24.4)	86 (26.2)
Ex-smokers	59 (74.7)	62 (73.8)	56 (70.9)	65 (75.6)	242 (73.8)
Mean (SD) smoking, pack-years	65.47 (31.5)	59.15 (27.9)	64.80 (35.0)	60.19 (43.8)	62.31 (35.1)
Pre-bronchodilator screeninga
Mean FEV1, L (SD)	1.23 (0.37)	1.27 (0.51)	1.25 (0.41)	1.24 (0.44)	1.25 (0.43)
Post-bronchodilator screeninga
Mean FEV1, L (SD)	1.40 (0.37)	1.43 (0.50)	1.41 (0.40)	1.39 (0.41)	1.41 (0.42)
Mean FVC, L (SD)	3.06 (0.59)	3.11 (0.66)	3.03 (0.56)	3.08 (0.59)	3.07 (0.60)
Mean FEV1/FVC, % (SD)	46.13 (10.95)	45.64 (11.50)	46.74 (11.17)	45.58 (11.14)	46.01 (11.15)
COPD severity according to GOLD, n (%)
Moderate/severe/very severeb	43/35/1 (54.4/44.3/1.3)	43/40/1 (51.2/47.6/1.2)	41/38/0 (51.9/48.1/0.0)	45/41/0 (52.3/47.7/0.0)	172/154/2 (52.4/47.0/0.6)
Pre-study respiratory medication use, n (%)
Long-acting inhaled anticholinergics	32 (40.5)	29 (34.5)	28 (35.4)	39 (45.4)	128 (39.0)
Short-acting inhaled anticholinergics	9 (11.4)	12 (14.3)	10 (12.7)	12 (14.0)	43 (13.1)
Long-acting β2-adrenergics	20 (25.3)	15 (17.9)	18 (22.8)	24 (27.9)	77 (23.5)
Short-acting inhaled β2-adrenergics	5 (6.3)	2 (2.4)	3 (3.8)	4 (4.7)	14 (4.3)
Inhaled steroids	16 (20.3)	11 (13.1)	9 (11.4)	21 (24.4)	57 (17.4)
Oral steroids	1 (1.3)	0 (0.0)	1 (1.3)	1 (1.2)	3 (0.9)

Notes:

a 10–15 minutes after 400 µg of salbutamol.

b Although the inclusion criteria only included moderate and severe COPD, two patients with very severe COPD were included.

Abbreviations: QD, once daily; SD, standard deviation; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease.

Figure 2 CONSORT diagram illustrating participant flow.

Abbreviations: QD, once daily; AE, adverse event; CONSORT, Consolidated Standards of Reporting Trials.

Efficacy

Lung function

All doses of olodaterol QD provided a significant increase in trough FEV₁ response compared to placebo following 4 weeks of treatment (P<0.0001) (Table 2), confirming the 24-hour bronchodilator activity of olodaterol. A clear dose–response relationship was observed, with a greater increase in bronchodilation with 5 µg and 10 µg of olodaterol compared to 2 µg (0.091 L for 2 µg, 0.132 L for 5 µg, and 0.132 L for 10 µg) (Table 2).

Table 2 Adjusted mean trough FEV₁ after 4 weeks of treatment

	Trough FEV1	Difference from placebo
	Treatment mean, L (SE)	Mean, L (SE)	95% CI
Placebo	−0.032 (0.015)
Olodaterol 2 µg QD	0.059 (0.015)	0.091 (0.020)*	0.051, 0.131
Olodaterol 5 µg QD	0.100 (0.015)	0.132 (0.021)*	0.091, 0.172
Olodaterol 10 µg QD	0.100 (0.015)	0.132 (0.020)*	0.092, 0.172

Note:

* P<0.0001.

Abbreviations: FEV₁, forced expiratory volume in 1 second; SE, standard error; CI, confidence interval; QD, once daily.

Statistically significant increases in trough FEV₁ responses were demonstrated with all doses of olodaterol compared to placebo at Weeks 1 and 2 (P<0.005). A clear dose response was observed (Figure 3A), with dose ordering across the three doses of olodaterol. The responses for the 5 µg and 10 µg doses of olodaterol were significantly greater than 2 µg of olodaterol (P<0.05). No statistically significant differences in trough FEV₁ responses between 5 µg and 10 µg of olodaterol were seen.

Figure 3 Adjusted mean trough FEV₁ (A) and FVC (B) responses (± standard error) at Weeks 1, 2, and 4 of olodaterol and placebo treatment.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.

All doses of olodaterol provided significant improvements in FEV₁ AUC_0–3 and peak FEV₁ responses over placebo after the first dose (P<0.0001). The dose response was maintained throughout the 4 weeks of treatment, and all three doses of olodaterol remained significantly different compared to placebo at Day 29 (P<0.0001) (Table 3). FEV₁ AUC_0–3 and peak FEV₁ responses were significantly higher with 5 µg of olodaterol compared to 2 µg (FEV₁ AUC_0–3, P<0.01; peak FEV₁, P<0.05) and with 10 µg of olodaterol compared to 2 µg (both end points, P<0.05), but there were no significant differences between 5 µg and 10 µg of olodaterol.

Table 3 Adjusted mean peak FEV₁ and FEV₁ AUC_0–3 after 4 weeks of treatment

	Treatment mean, L (SE)	Difference from placebo
		Mean, L (SE)	95% CI
Peak FEV1
Placebo	0.025 (0.017)
Olodaterol 2 µg QD	0.170 (0.017)	0.146 (0.023)*	0.101, 0.191
Olodaterol 5 µg QD	0.227 (0.017)	0.202 (0.023)*	0.157, 0.247
Olodaterol 10 µg QD	0.220 (0.017)	0.196 (0.023)*	0.151, 0.240
FEV1 AUC0–3
Placebo	−0.020 (0.017)
Olodaterol 2 µg QD	0.118 (0.016)	0.138 (0.022)*	0.095, 0.182
Olodaterol 5 µg QD	0.177 (0.017)	0.197 (0.022)*	0.154, 0.241
Olodaterol 10 µg QD	0.173 (0.016)	0.193 (0.022)*	0.150, 0.236

Note:

* P<0.0001.

Abbreviations: Peak FEV₁, peak forced expiratory volume in 1 second from 0 hour to 3 hours; FEV₁ AUC_0–3, forced expiratory volume in 1 second area under the curve from 0 hour to 3 hours; SE, standard error; CI, confidence interval; QD, once daily.

Similarly, all doses of olodaterol were statistically superior to placebo for trough FVC at Weeks 1 and 2, peak FVC, and FVC AUC_0–3 responses after 4 weeks of treatment (Table 4). Trough FVC outcomes were all improved versus placebo (Table 4; Figure 3B).

Table 4 Adjusted mean trough FVC, peak FVC, and FVC AUC_0–3 after 4 weeks of treatment

	Treatment mean, L (SE)	Difference from placebo
		Mean, L (SE)	95% CI
Trough FVC
Placebo	−0.037 (0.033)
Olodaterol 2 µg QD	0.154 (0.032)	0.191 (0.043)*	0.107, 0.275
Olodaterol 5 µg QD	0.154 (0.033)	0.191 (0.043)*	0.106, 0.276
Olodaterol 10 µg QD	0.150 (0.032)	0.187 (0.042)*	0.103, 0.270
Peak FVC
Placebo	0.109 (0.038)
Olodaterol 2 µg QD	0.362 (0.037)	0.253 (0.050)*	0.155, 0.351
Olodaterol 5 µg QD	0.351 (0.038)	0.242 (0.050)*	0.142, 0.341
Olodaterol 10 µg QD	0.335 (0.036)	0.226 (0.050)*	0.129, 0.324
FVC AUC0–3
Placebo	0.004 (0.036)
Olodaterol 2 µg QD	0.257 (0.035)	0.253 (0.047)*	0.160, 0.345
Olodaterol 5 µg QD	0.254 (0.036)	0.250 (0.047)*	0.156, 0.343
Olodaterol 10 µg QD	0.237 (0.035)	0.233 (0.047)*	0.141, 0.325

Note:

* P<0.0001.

Abbreviations: FVC, forced vital capacity; Peak FVC, peak FVC from 0 hour to 3 hours; AUC_0–3, area under the curve from 0 hour to 3 hours; SE, standard error; CI, confidence interval; QD, once daily.

The FEV₁ time profiles after treatment with 2 µg, 5 µg, and 10 µg of olodaterol are illustrated in Figure 4A and B, and show a significant increase in FEV₁ versus placebo within 30 minutes of drug administration, which was maintained up to 3 hours post-dose (P<0.0001). This pattern of dose response was consistent over 4 weeks of treatment, although there was no apparent dose separation between 5 µg and 10 µg of olodaterol at Day 29 (Week 4). The FVC time profiles after olodaterol administration followed a similar pattern to those for FEV₁, with all doses of olodaterol showing improvements versus placebo (Figure 4C and D).

Figure 4 Mean FEV₁ (A and B) and FVC (C and D) responses from −10 minutes to 3 hours on Day 1 (first administration) and Week 4.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; min, minutes.

Adjusted mean weekly morning (predose) and evening peak expiratory flow rate readings showed significant improvements compared to placebo for all doses of olodaterol (P<0.0001). The magnitude of difference from placebo in both morning and evening readings was similar, with a range of 18 to 37 L/min and 23 to 37 L/min, respectively.

Rescue medication use was statistically significantly decreased (P<0.05) following treatment with 5 µg and 10 µg of olodaterol compared to placebo over 4 weeks of treatment (except with 10 µg of olodaterol at Week 1).

During the course of the treatment period with each dose of olodaterol, COPD symptom scores averaged between “none” and “mild”. There was no significant improvement in coughing, tightness of chest, or wheezing over the treatment period. However, there was directional improvement in shortness of breath with olodaterol compared to placebo (P<0.05), although no dose response was observed between the olodaterol groups.

The adjusted mean values for PGE were in the “good” range with all doses of olodaterol at all time points. At Day 29, however, PGE scores associated with 2 µg and 10 µg of olodaterol were significantly greater than placebo (P<0.01) but not with 5 µg of olodaterol.

Pharmacokinetics

Plasma concentrations after treatment with 2 µg of olodaterol were mostly below the limit of quantification (2 pg/mL). The mean plasma concentration–time profiles for olodaterol after treatment with 5 µg or 10 µg are presented in Figure 5. Peak plasma concentrations following inhalation (C_max and C_max at steady-state [C_max,ss]) were observed within 20 minutes (t_max 0.283 hours and 0.300 hours; t_max at steady-state 0.333 hours and 0.300 hours for 5 µg and 10 µg of olodaterol, respectively; Tables 5 and 6). The apparent clearance at steady-state was 798 mL/min and 1,040 mL/min following administration of 5 µg and 10 µg of olodaterol, respectively. The accumulation ratios based on C_max and area under the curve from 0 hour to 1 hour (AUC_0–1) were low (1.59 to 1.77; Table 6).

Table 5 Pharmacokinetic parameters of olodaterol following first administration

Olodaterol Day 1	n	gMean (gCV%)
		Olodaterol 5 µg	Olodaterol 10 µg
Cmax, pg/mL	53/81	4.17 (46.7)	8.22 (58.3)
Cmax,norm, pg/mL/µg	53/81	0.833 (46.7)	0.822 (58.3)
tmax,a h	53/81	0.283 (0.0500–0.633)	0.300 (0.0500–0.667)
AUC0–1, pg·h/mL	30/77	3.67 (35.6)	6.08 (50.8)
AUC0–1,norm, pg·h/mL/µg	30/77	0.753 (35.6)	0.608 (50.8)

Note:

a Median (minimum–maximum).

Abbreviations: gMean, geometric mean; gCV, geometric coefficient of variation; C_max, maximum measured concentration of olodaterol in plasma; norm, dose normalized; t_max, time from dosing to maximum measured concentration of olodaterol in plasma; h, hours; AUC_0–1, area under the curve from 0 hour to 1 hour.

Table 6 Pharmacokinetic parameters of olodaterol following last administration

Olodaterol Week 4	n	gMean (gCV%)
		Olodaterol 5 µg	Olodaterol 10 µg
Cmax,ss, pg/mL	67/78	5.92 (57.4)	13.1 (58.6)
Cmax,ss,norm, pg/mL/µg	67/78	1.18 (57.4)	1.31 (58.6)
tmax,ss,a h	67/78	0.333 (0.0500–0.883)	0.300 (0.0830–1.00)
AUC0–1,ss, pg·h/mL	64/77	4.85 (54.6)	10.8 (54.0)
AUC0–1,ss,norm, pg·h/mL/µg	64/77	0.970 (54.6)	1.08 (54.0)
AUC0–3,ss, pg·h/mL	51/76	13.9 (45.4)	26.9 (51.7)
AUC0–3,ss,norm, pg·h/mL/µg	51/76	2.79 (45.4)	2.69 (51.7)
AUC0–24,ss, pg·h/mL	27/62	104 (36.4)	160 (40.7)
AUC0–24,ss,norm, pg·h/mL/µg	27/62	20.9 (36.4)	16.0 (40.7)
CL/Fss, mL/min	27/62	798 (36.4)	1,040 (40.7)
$R_{\mathrm{A},C_{\max }}$	47/74	1.59 (46.7)	1.60 (55.3)
$R_{\mathrm{A},{\text{AUC}}_{0-1}}$	28/71	1.69 (39.9)	1.77 (47.7)

Note:

a Median (minimum–maximum).

Abbreviations: gMean, geometric mean; gCV, geometric coefficient of variation; C_max, maximum measured concentration of olodaterol in plasma; ss, steady state; norm, dose normalized; t_max, time from dosing to maximum measured concentration of olodaterol in plasma; h, hours; AUC_0–1, area under the curve from 0 hour to 1 hour; AUC_0–3, area under the curve from 0 hour to 3 hours; AUC_0–24, area under the curve from 0 hour to 24 hours; CL/F, apparent clearance; min, minutes; $R_{\mathrm{A},C_{\max }}$, accumulation ratio based on C_max; $R_{\mathrm{A},{\text{AUC}}_{0-1}}$, accumulation ratio based on AUC_0–1.

Figure 5 Mean plasma concentration–time profiles for olodaterol.

Notes: Plasma concentrations after olodaterol 2 µg inhalation were too low to be quantified in most patients; therefore, mean plasma concentration profiles are not displayed.

The distributions of dose-normalized systemic exposure parameters (C_max,norm, AUC_0–1,norm, C_max,ss,norm, and AUC_{0–1,ss,norm}) overlapped between the olodaterol 2 µg, 5 µg, and 10 µg groups; hence, systemic exposure was considered to increase proportionally within the dose range investigated (C_max,ss,norm and AUC_{0–1,ss,norm} in Figure 6).

Figure 6 Dose-normalized steady-state maximum concentrations (A) and AUC_0–1 (B) of olodaterol.

Note: Plasma concentrations after olodaterol 2 µg inhalation in most patients were below the limit of quantification; therefore, a gMean was not calculated.
Abbreviations: gMean, geometric mean; C_max,ss,norm, maximum measured concentration of olodaterol in plasma, steady-state, dose-normalized; AUC_{0–1,ss,norm}, area under the curve from 0 hour to 1 hour, steady-state, dose-normalized.

Safety

All doses of olodaterol were well tolerated, with the majority of AEs reported as mild to moderate in intensity. The number of patients who experienced any AE under treatment was well balanced across groups (Table 7). The most commonly reported AEs were nasopharyngitis, COPD exacerbation, and myalgia (Table 7). A total of seven patients receiving 2 µg, 5 µg, and 10 µg of olodaterol experienced at least one serious AE during the study that necessitated hospitalization (Table 7). Serious AEs were evenly distributed across all treatment groups and system organ classes; there was no indication that these were related to study medication. No deaths occurred during the study.

Table 7 Summary of AEs under treatmenta

	Placebo, n (%)	Olodaterol 2 µg, n (%)	Olodaterol 5 µg, n (%)	Olodaterol 10 µg, n (%)
Total	79 (100.0)	84 (100.0)	79 (100.0)	86 (100.0)
Patients with AEs	28 (35.4)	28 (33.3)	25 (31.6)	36 (41.9)
Frequently reported AEsb
Nasopharyngitis	3 (3.8)	9 (10.7)	3 (3.8)	5 (5.8)
COPD exacerbation	3 (3.8)	3 (3.6)	3 (3.8)	1 (1.2)
Myalgia	4 (5.1)	0 (0.0)	0 (0.0)	0 (0.0)
Patients with serious AEs	2 (2.5)	3 (3.6)	1 (1.3)	3 (3.5)

Note:

a AEs under treatment were AEs observed during, and up to 12 days following, treatment;

b AEs with an incidence >3% in any one of the treatment groups.

Abbreviations: AE, adverse event; COPD, chronic obstructive pulmonary disease.

No clinically relevant changes in laboratory parameters and vital signs were reported. Outcomes from the 12-lead electrocardiogram showed no dose-dependent effects of olodaterol on conduction abnormalities, heart rate, or QT interval (including QT interval corrected by Bazett’s formula and Fridericia’s formula).

Discussion

This 4-week, multidose study provides evidence for the 24-hour bronchodilator efficacy and tolerability of QD administration of olodaterol in Japanese patients with COPD.

Statistically significant improvements in trough FEV₁, peak FEV₁, and FEV₁ AUC_0–3 responses were observed following all doses of olodaterol compared to placebo after 4 weeks of treatment. Trough FEV₁ response was chosen as the primary end point for this study, as this measure gives a good indication of potential for 24-hour bronchodilator activity. Thus, the consistent improvement in trough FEV₁ responses across all time points compared to placebo supports the potential for QD dosing. Findings from this study replicate those from previous single-dose-administration studies¹³ and add to the increasing bank of evidence that treatment with olodaterol QD provides effective 24-hour bronchodilation in patients with COPD regardless of ethnicity.

In all, 2 µg, 5 µg, and 10 µg of olodaterol QD provided a significant increase in trough FEV₁ response compared to placebo after 4 weeks of treatment; FVC responses supported those observed for FEV₁. Furthermore, a clear dose–response relationship was observed with respect to pulmonary function in this patient population, with 2 µg of olodaterol reported to lie on the steep portion of the dose–response curve. However, the efficacy of 5 µg and 10 µg of olodaterol was quite similar, suggesting that both doses of the study medication lie on or close to the plateau of the dose–response curve. These data have helped to provide the necessary information for selection of doses within an appropriate therapeutic range. Therefore, in light of these findings, 5 µg or 10 µg of olodaterol QD may be considered the optimal dose for 4-week administration in Japanese patients with COPD.

Although inhalation is the preferred administration route for treating COPD for a topical, rather than a systemic, bronchodilator effect, systemic pharmacokinetic data may provide a clue to evaluate safety. This trial was, therefore, conducted to evaluate lung function and pharmacokinetic parameters in Japanese patients and to assess appropriate doses of olodaterol in these patients. The findings from this study are broadly similar to another Phase II olodaterol dose-finding study (1222.5; NCT0452400) in non-Japanese patients with COPD, which provided evidence of the bronchodilator efficacy of 2 µg, 5 µg, 10 µg, and 20 µg of olodaterol QD over 24 hours.¹⁰ Regarding the comparison of the systemic exposure of olodaterol, systemic exposure tended to be higher in the current study than in the non-Japanese study (ie, geometric mean C_max,ss 5.92 pg/mL versus 4.02 pg/mL [5 µg], 13.1 pg/mL versus 7.13 pg/mL [10 µg], and AUC_0–1,ss 4.85 pg·h/mL versus 3.38 pg·h/mL [5 µg], 10.8 pg·h/mL versus 5.76 pg·h/mL [10 µg]). The main metabolic pathway of olodaterol clearance is related to uridine 5′-diphospho-g lucuronosyltransferase (UGT), for which racial difference in activity has not been reported. The deposition pattern of (and, therefore, systemic exposure to) inhaled medications results from the interplay of device, formulation, and inhalation technique.¹⁴ The device and formula used in the two studies were identical, and it is unlikely that variation in technique was the reason for the difference between the Japanese and non-Japanese patients included in the two studies. Furthermore, to date there has been no reported evidence of any general ethnic difference in systemic exposure to inhaled medication, including β-agonists. Although the reason for the difference in systemic exposure between the studies with Japanese and non-Japanese patients is unclear, all dosages of olodaterol investigated in the study were well tolerated in Japanese patients with COPD across a broad range of patient characteristics. Occurrences of AEs were low, equally distributed across all treatment groups, and mild to moderate in intensity.

With regard to efficacy, in the study with non-Japanese patients, the change from baseline in trough FEV₁ was 0.046, 0.082, and 0.109 with 2 µg, 5 µg, and 10 µg of olodaterol.¹⁰

Interestingly, efficacy outcomes in non-Japanese patients showed a clear distinction between 2 µg of olodaterol and 10 µg and 20 µg of olodaterol; however, in Study 1222.5, the positioning of the 5 µg dose with respect to 2 µg and 10 µg of olodaterol was variable, indicating that further evaluation of the doses is warranted. However, taking into account the results from both studies, we can conclude that the FEV₁ dose response in Japanese patients is similar to that in non-Japanese patients.

In addition to evidence for the 24-hour bronchodilator efficacy in Japanese patients with COPD being provided, pharmacokinetic analysis indicated that exposure to olodaterol increased dose proportionally within the dose range investigated and was not affected by age, sex, weight, or renal, liver, or lung function. Encouragingly, there was little effect on exposure for patients taking cytochrome p450, UGT, or P-glycoprotein inhibitors, although the number of patients taking these co-medications was small.

Outcomes from this study indicate that the optimal dose of olodaterol inhalation solution is 5 µg or 10 µg for a 4-week administration in Japanese patients with COPD. In light of the 24-hour bronchodilatory efficacy observed with 5 µg and 10 µg of olodaterol and together with outcomes from Study 1222.5 and the international Phase III program,^15–18 a QD posology is likely to be a viable strategy for Japanese patients with COPD to improve treatment adherence, particularly as outcomes from a recent study have demonstrated that adherence levels are strongly associated with daily dosing frequency. COPD drugs with QD dosing had the highest adherence levels, with adherence declining consistently as the frequency of dosing increased.^7,19,20

Conclusion

QD administration of 2 µg, 5 µg, and 10 µg of olodaterol demonstrated effective 24-hour bronchodilation after 4 weeks in a dose-dependent manner in Japanese patients with COPD. In particular, treatment with 5 µg and 10 µg of olodaterol QD demonstrated an increase in lung function compared to 2 µg of olodaterol QD. No safety or tolerability concerns were identified, and systemic exposure to olodaterol was not affected by age, sex, weight, or renal, liver, or lung function. Data from this Phase II study were consistent with outcomes from other Phase II studies and together provided the rationale to further investigate 5 µg and 10 µg of olodaterol in a Phase III clinical program in COPD.

Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Acknowledgments

The authors received no compensation related to the development of the manuscript. This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. Medical writing assistance was provided by Tanya Chaudry, PhD, of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG.

Disclosure

MI has received lecture fees from AstraZeneca, GlaxoSmithKline, Nippon Boehringer Ingelheim, and Novartis Pharma. YF has received honoraria for consultancy from Eisai, Otsuka Pharmaceuticals, and Nippon Boehringer Ingelheim. AT, TI, YT, ALH, and CK are all employees of Boehringer Ingelheim.